After eight weeks of therapy, the ROS and MDA values for Group R were statistically significantly lower than those for Group C, while the SOD value for Group R was statistically significantly higher than that for Group C.
The ROS is a major cause of oxidative stress, the SOD is an antioxidant enzyme, while the MDA is a degradation product of lipid peroxidation substances produced as a result of lipid oxidation.
From these, adding RE therapy to the standard of care was inferred to be effective in comprehensively improving oxidative stress in patients with metabolic syndrome.